Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial
| Autor: | AK Mylin, Lene Meldgaard Knudsen, Peter Gimsing, Hans Erik Johnsen, Torben Plesner, Niels Frost Andersen, Niels Abildgaard, Torben Mourits-Andersen, Henrik Gregersen, Annette Juul Vangsted |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2009 |
| Předmět: |
Oncology
medicine.medical_specialty medicine.medical_treatment Placebo-controlled study multiple myeloma clinical trial fludarabine Placebo Article Targeted therapy Fludarabine Internal medicine medicine Multiple myeloma business.industry lcsh:RC633-647.5 Hematology lcsh:Diseases of the blood and blood-forming organs Interim analysis medicine.disease Surgery Clinical trial Toxicity business medicine.drug |
| Zdroj: | Hematology Reviews Hematology Reviews; Volume 1; Issue 2; Pages: e11 Hematology Reports, Vol 1, Iss 2, Pp e11-e11 (2009) Aalborg University Johnsen, H E, Knudsen, L M, Mylin, A K, Gimsing, P, Gregersen, H, Abildgaard, N, Andersen, N F, Plesner, T, Vangsted, A J & Mouritz-Andersen, T 2009, ' Up-front fludarabine impairs stem cell harvest in multiple myeloma: report from an interim analysis of the NMSG 13/03 randomized placebo controlled phase II trial ', Hematology Reviews, vol. 1, no. 2, pp. 62-64 . |
| ISSN: | 1970-6790 |
| Popis: | Udgivelsesdato: 2009 The impact of chemotherapy resistant B cells in multiple myeloma (MM) needs to be evaluated by in vivo targeted therapy. Here we report the conclusions from a phase II randomized, placebo controlled trial adding fludarabine to the induction with cyclophosphamide-dexamethasone. Based on an interim toxicity and safety analysis, the trial was stopped following inclusion of 34 of a planned 80 patients due to a reduced number of patients (4/17) actually harvested in the experimental arm compared to the control arm (11/17; p lower than 0.05). In conclusion, the scheduled fludarabine dosage in 2 cycles combined with alkylating therapy impairs stem cell mobilization and standard therapy in young MM patients and should not be administrated up-front. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|